TrialBreast cancer research : BCR2021

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

Peter Schmid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.